2014
DOI: 10.2147/ijn.s41822
|View full text |Cite
|
Sign up to set email alerts
|

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Abstract: Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, and 6 are common in Asia. The aim of HCV treatment is to eradicate the virus by effective therapeutic agents; viral clearance is durable after long-term post-treatment follow-up. In most Asian countries, peginterferon… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
8
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 16 publications
(8 citation statements)
references
References 129 publications
0
8
0
Order By: Relevance
“…Among those with chronic HCV infection, 30% will advance to liver cirrhosis and liver cancer, which is the leading cause of death for patients with hepatitis C in Asia. PegIFN plus RBV therapy according to response-guide therapy for 24 to 48 weeks is the standard anti-viral therapy in Asia [ 6 ]. However, the sequelae of PegIFN plus RBV therapy is an another healthcare problem.…”
Section: Discussionmentioning
confidence: 99%
“…Among those with chronic HCV infection, 30% will advance to liver cirrhosis and liver cancer, which is the leading cause of death for patients with hepatitis C in Asia. PegIFN plus RBV therapy according to response-guide therapy for 24 to 48 weeks is the standard anti-viral therapy in Asia [ 6 ]. However, the sequelae of PegIFN plus RBV therapy is an another healthcare problem.…”
Section: Discussionmentioning
confidence: 99%
“…Although the overall SVR rates in our patients with acute or chronic HCV infection were satisfactory, the response rates were significantly reduced in patients with chronic HCV infection who did not achieve RVR. Considering the limited availability and affordability of DAA in many Asian countries, these agents should be reserved for treatment-naïve HIV-infected Asian patients who are ineligible for or fail to achieve RVR by peginterferon plus ribavirin therapy, and for those who are intolerant, or fail prior peginterferon plus ribavirin therapy 45 46 .…”
Section: Discussionmentioning
confidence: 99%
“…Among patients with chronic HCV infection, about 20% of them will evolve to cirrhosis over a period of 20–30 years. Once cirrhosis is established, the annual rates of developing hepatic decompensation and hepatocellular carcinoma (HCC) are 3–6% and 1–4%, respectively 2 , 3 . In addition to increasing the risks of liver-related morbidity and mortality, HCV infection is also associated with various extra-hepatic manifestations which further compromised the patients’ health outcome and quality of life 4 .…”
Section: Introductionmentioning
confidence: 99%